



DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

- POLICY:** Inflammatory Conditions – Tremfya Drug Quantity Management Policy
– Per Days
- Tremfya® (guselkumab subcutaneous injection – Janssen)

REVIEW DATE: 01/03/2024

INSTRUCTIONS FOR USE

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

CIGNA NATIONAL FORMULARY COVERAGE:

OVERVIEW

Tremfya, an interleukin (IL)-23 blocker, is indicated for the following uses:¹

- **Plaque psoriasis**, in adults with moderate to severe disease who are candidates for systemic therapy or phototherapy.
- **Psoriatic arthritis**, in adults with active disease (given ± a conventional synthetic disease-modifying antirheumatic drug).

Dosing

Tremfya is administered by a subcutaneous (SC) injection.¹ For both plaque psoriasis and psoriatic arthritis, the recommended dose is 100 mg SC at Week 0 and Week 4, then 100 mg SC once every 8 weeks thereafter.

Availability

Tremfya is available in the following forms:¹

- 100 mg/mL single-dose patient-controlled injector
- 100 mg/mL single-dose prefilled syringe

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Tremfya, and to manage potential premature dose escalation. If the Drug Quantity Management rule is not met at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Drug Quantity Limits

Product	Strength and Form	Retail and Home Delivery Maximum Quantity per 56 Days
Tremfya® (guselkumab subcutaneous injection)	100 mg patient-controlled injector	1 injector
	100 mg/mL prefilled syringe	1 syringe

Inflammatory Conditions – Tremfya Drug Quantity Management Policy – Per Days product(s) is(are) covered as medically necessary when the following criteria is(are) met. Any other exception is considered not medically necessary.

CRITERIA

1. If the patient is initiating treatment or requires additional induction dosing, as verified by the absence of claims for Tremfya in the past 130 days, approve a one-time override for 2 prefilled syringes or patient-controlled injectors at retail or home delivery.

REFERENCES

1. Tremfya® subcutaneous injection [prescribing information]. Horsham, PA: Janssen; November 2023.

HISTORY

Type of Revision	Summary of Changes	Review Date
Early Annual Revision	No criteria changes. Policy was updated to reflect the existing quantity limits when a product is obtained via home delivery.	12/19/2022
Annual Revision	No criteria changes.	01/03/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc.,

Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. ©
2024 The Cigna Group.